https://orcid.org/0000-0003-1750-657X
References
- Awasthi R, Maier HJ, Zhang J, Lim S. Kymriah® (tisagenlecleucel) - an overview of the clinical development journey of the first approved CAR-T therapy. Hum Vaccin Immunother. 2023;19(1):2210046. doi:10.1080/21645515.2023.2210046.
- Whitehead E. First pediatric patient to receive CAR T-cell therapy, celebrates cure 10 years later. Children’s Hospital of Philadelphia [accessed 2022 May 11]. https://www.chop.edu/news/emily-whitehead-first-pediatric-patient-receive-car-t-cell-therapy-celebrates-cure-10-years.
- Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, et al. Decade-long leukemia remissions with the persistence of CD4+ CAR T cells. Nature. 2022;602:503–4. doi:10.1038/s41586-021-04390-6.
- Grupp S, Kalos M, Barrett D, Aplenc R, Porter D, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–1518. doi:10.1056/NEJMoa1215134.
- Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359–371. doi:10.1038/s41571-023-00754-1.
- Ledford H. Last-resort cancer therapy holds back disease for more than a decade. Nature. 2022;602(7896):196. doi:10.1038/d41586-022-00241-0.
- Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, Horwitz EM, Grupp SA, Maus MV, Locke FL, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024. doi:10.1038/s41591-023-02767-w.
- Kalos M, Levine B, Porter D, Katz S, Grupp S, Bagg A, June C. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. doi:10.1126/scitranslmed.3002842.
- Ludwig B. Patient who helped pioneer cancer immunotherapy at Penn, dies at 75 of COVID-19. The Philadelphia Inquirer, LLC; 2023 [accessed 2021 Feb 17]. https://www.inquirer.com/obituaries/covid-19-claims-bill-ludwig-cancer-immunotherapy-pioneer-penn-20210217.html.
- Maus M. A decade of CAR T cell evolution. Nat Cancer. 2022;3(3):270–271. doi:10.1038/s43018-022-00347-4.
- Flemming A. Cytotoxic CD4+ CAR T cells implicated in long-term leukaemia remission. Nat Rev Immunol. 2022;22(3):146. doi:10.1038/s41577-022-00689-1.
- Testa U, Sica S, Pelosi E, Castelli G, Leone G. CAR-T cell therapy in B-cell acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2024;16(1):e2024010. doi:10.4084/MJHID.2024.010.
- Bouzianas D, Bouziana S. A decade of CD4+ chimeric antigen receptor T-cell evolution in two chronic lymphocytic leukemia patients: were chronic lymphocytic leukemia cells present? Explor Target Antitumor Ther. 2023;4(5):1128–1135. doi:10.37349/etat.2023.00186.
- Spiegel JY, Jain MD, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, Lekakis LJ, Reagan PM, Oluwole OO, McGuirk JP, et al. Five year outcomes of patients with large B-Cell lymphoma treated with standard-of-care Axicabtagene Ciloleucel: results from the US lymphoma CAR-T cell consortium. Blood. 2023;142(Supplement 1):1032. doi:10.1182/blood-2023-179868.
- Rosenbaum L. Tragedy, perseverance, and chance - the story of CAR-T therapy. N Engl J Med. 2017;377(14):1313–1315. doi:10.1056/NEJMp1711886.
- Biasco L, Scala S, Basso Ricci L, Dionisio F, Baricordi C, Calabria A, Giannelli S, Cieri N, Barzaghi F, Pajno R, et al. In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. Sci Transl Med. 2015;7(273):273ra13. doi:10.1126/scitranslmed.3010314.
- Oliveira G, Ruggiero E, Stanghellini MT, Cieri N, D’Agostino M, Fronza R, Lulay C, Dionisio F, Mastaglio S, Greco R, et al. Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. Sci Transl Med. 2015;7(317):317ra198. doi:10.1126/scitranslmed.aac8265.